Rigel says Phase 3 AcceleRET-Lung trial meets primary endpoint for GAVRETO in NSCLC

Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc.

RIGL

0.00
  • Rigel Pharmaceuticals outlined new data disclosures for its oncology portfolio, led by final Phase 3 results for GAVRETO (pralsetinib) in first-line RET fusion-positive non-small cell lung cancer scheduled for oral presentation at the ASCO Annual Meeting on May 29, 2026.
  • The study readout supports pralsetinib’s clinical benefit versus standard treatment, with a safety profile that included infection-related risk that the company indicated can be managed with closer monitoring.
  • Additional pralsetinib updates will be presented in future poster sessions at ASCO, including a final analysis in RET-altered thyroid cancer from the ARROW trial.
  • Rigel also flagged upcoming ASCO and EHA presentations for REZLIDHIA (olutasidenib), including real-world evidence in relapsed or refractory IDH1-mutated AML that supports its use following prior venetoclax therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rigel Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605211717PR_NEWS_USPR_____SF65106) on May 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.